NIH issues solicitation for radiation medical countermeasures
The National Institute of Allergy and Infectious Diseases, the NIH and the Department of Health and Human Services are soliciting proposals to advance the development of candidate medical countermeasures toward eventual approval by the U.S. Food and Drug Administration. Candidate MCMs can enter the evaluation and development pathways at all different stages, including early research and post marketing.
The NIAID, NIH and DHHS will evaluate proposals based on underlying data to support the MCMs' amelioration of radiation-induced thrombocytopenia, data on an improved survival rate and the suitability, adequacy, soundness and comprehensiveness of the proposed methodology and scientific approach to advance the candidate MCM. Good laboratory practices, good manufacturing practices, and the adequacy of equipment, facilities and technical personnel will also be considered in the evaluation.
The NIAID estimates it will award $1 million to $2 million per contract award per year, though the total cost for the award may very depending on the scope of the project and the technical objectives of the award. The proposed performance period should not exceed three years.
The response date for the solicitation is July 1.
The NIAID is charged by the DHHS to develop products for treatment of radiation exposures resulting from attacks to the stage of advanced product development by the Biomedical Advanced Research and Development Authority or for acquisition as part of the Project BioShield Act of 2004.